Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma.

ABSTRACT: Multiple myeloma (MM) is the second most common haematological malignancy and is an incurable disease of neoplastic plasma cells (PC). Newly diagnosed MM patients currently undergo lengthy genetic testing to match chromosomal mutations with the most potent drug/s to decelerate disease progression. With only 17% of MM patients surviving 10-years postdiagnosis, faster detection and earlier intervention would unequivocally improve outcomes. Here, we show that the cell surface protein desmoglein-2 (DSG2) is overexpressed in ~ 20% of bone marrow biopsies from newly diagnosed MM patients. Importantly, DSG2 expression was strongly predictive of poor clinical outcome, with patients expressing DSG2 above the 70^th percentile exhibiting an almost 3-fold increased risk of death. As a progno

SUBMITTER: Ebert LM 

PROVIDER: S-EPMC8936512 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature